Cargando…

Predictive markers for efficiency of the amino-acid deprivation therapies in cancer

Amino acid deprivation therapy (AADT) is a promising strategy for developing novel anticancer treatments, based on variations in metabolism of healthy and malignant cells. L-asparaginase was the first amino acid-degrading enzyme that received FDA approval for the treatment of acute lymphoblastic leu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokrovsky, Vadim S., Abo Qoura, Louay, Morozova, Elena, Bunik, Victoria I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669297/
https://www.ncbi.nlm.nih.gov/pubmed/36405587
http://dx.doi.org/10.3389/fmed.2022.1035356
_version_ 1784832067763175424
author Pokrovsky, Vadim S.
Abo Qoura, Louay
Morozova, Elena
Bunik, Victoria I.
author_facet Pokrovsky, Vadim S.
Abo Qoura, Louay
Morozova, Elena
Bunik, Victoria I.
author_sort Pokrovsky, Vadim S.
collection PubMed
description Amino acid deprivation therapy (AADT) is a promising strategy for developing novel anticancer treatments, based on variations in metabolism of healthy and malignant cells. L-asparaginase was the first amino acid-degrading enzyme that received FDA approval for the treatment of acute lymphoblastic leukemia (ALL). Arginase and arginine deiminase were effective in clinical trials for the treatment of metastatic melanomas and hepatocellular carcinomas. Essential dependence of certain cancer cells on methionine explains the anticancer efficacy of methionine-g-lyase. Along with significant progress in identification of metabolic vulnerabilities of cancer cells, new amino acid-cleaving enzymes appear as promising agents for cancer treatment: lysine oxidase, tyrosine phenol-lyase, cysteinase, and phenylalanine ammonia-lyase. However, sensitivity of specific cancer cell types to these enzymes differs. Hence, search for prognostic and predictive markers for AADT and introduction of the markers into clinical practice are of great importance for translational medicine. As specific metabolic pathways in cancer cells are determined by the enzyme expression, some of these enzymes may define the sensitivity to AADT. This review considers the known predictors for efficiency of AADT, emphasizing the importance of knowledge on cancer-specific amino acid significance for such predictions.
format Online
Article
Text
id pubmed-9669297
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96692972022-11-18 Predictive markers for efficiency of the amino-acid deprivation therapies in cancer Pokrovsky, Vadim S. Abo Qoura, Louay Morozova, Elena Bunik, Victoria I. Front Med (Lausanne) Medicine Amino acid deprivation therapy (AADT) is a promising strategy for developing novel anticancer treatments, based on variations in metabolism of healthy and malignant cells. L-asparaginase was the first amino acid-degrading enzyme that received FDA approval for the treatment of acute lymphoblastic leukemia (ALL). Arginase and arginine deiminase were effective in clinical trials for the treatment of metastatic melanomas and hepatocellular carcinomas. Essential dependence of certain cancer cells on methionine explains the anticancer efficacy of methionine-g-lyase. Along with significant progress in identification of metabolic vulnerabilities of cancer cells, new amino acid-cleaving enzymes appear as promising agents for cancer treatment: lysine oxidase, tyrosine phenol-lyase, cysteinase, and phenylalanine ammonia-lyase. However, sensitivity of specific cancer cell types to these enzymes differs. Hence, search for prognostic and predictive markers for AADT and introduction of the markers into clinical practice are of great importance for translational medicine. As specific metabolic pathways in cancer cells are determined by the enzyme expression, some of these enzymes may define the sensitivity to AADT. This review considers the known predictors for efficiency of AADT, emphasizing the importance of knowledge on cancer-specific amino acid significance for such predictions. Frontiers Media S.A. 2022-11-03 /pmc/articles/PMC9669297/ /pubmed/36405587 http://dx.doi.org/10.3389/fmed.2022.1035356 Text en Copyright © 2022 Pokrovsky, Abo Qoura, Morozova and Bunik. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Pokrovsky, Vadim S.
Abo Qoura, Louay
Morozova, Elena
Bunik, Victoria I.
Predictive markers for efficiency of the amino-acid deprivation therapies in cancer
title Predictive markers for efficiency of the amino-acid deprivation therapies in cancer
title_full Predictive markers for efficiency of the amino-acid deprivation therapies in cancer
title_fullStr Predictive markers for efficiency of the amino-acid deprivation therapies in cancer
title_full_unstemmed Predictive markers for efficiency of the amino-acid deprivation therapies in cancer
title_short Predictive markers for efficiency of the amino-acid deprivation therapies in cancer
title_sort predictive markers for efficiency of the amino-acid deprivation therapies in cancer
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669297/
https://www.ncbi.nlm.nih.gov/pubmed/36405587
http://dx.doi.org/10.3389/fmed.2022.1035356
work_keys_str_mv AT pokrovskyvadims predictivemarkersforefficiencyoftheaminoaciddeprivationtherapiesincancer
AT aboqouralouay predictivemarkersforefficiencyoftheaminoaciddeprivationtherapiesincancer
AT morozovaelena predictivemarkersforefficiencyoftheaminoaciddeprivationtherapiesincancer
AT bunikvictoriai predictivemarkersforefficiencyoftheaminoaciddeprivationtherapiesincancer